Celsion Corp
Затворен
0
Преглед
Промяна на цената на акция
24 ч
Минимум
Максимум
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +502.69% upside |
Celsion Corp Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Celsion Corp Прогноза
Ценова цел
By TipRanks
502.69% нагоре
12-месечна прогноза
Среден 15.67 USD 502.69%
Висок 25 USD
Нисък 10 USD
Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Celsion Corp през последните три месеца.
Финанси
$
Относно Celsion Corp
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
